Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...
Red blood cells (RBCs), traditionally regarded as passive oxygen carriers, are now recognized as highly dynamic regulators of immune and vascular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results